Thyrocare Technologies Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, alongside the re-appointment of M/s Ernst & Young LLP as internal auditors for the financial year 2026-27. On a standalone basis, revenue from operations reached ₹225.66 Crores, marking a sequential growth of 7.11% from ₹210.67 Crores in the previous quarter (Q4 FY26) and a robust year-on-year increase of 26.14% compared to ₹178.89 Crores in the corresponding quarter of the previous year (Q1 FY26). Standalone net profit for the period stood at ₹50.17 Crores, reflecting an increase of 15.12% QoQ from ₹43.58 Crores and a surge of 39.17% YoY from ₹36.05 Crores. On a consolidated basis, revenue from operations grew to ₹240.02 Crores, up 7.18% QoQ from ₹223.95 Crores and 24.34% YoY from ₹193.03 Crores, while consolidated net profit after tax reached ₹51.33 Crores, representing a 5.40% QoQ growth from ₹48.70 Crores and a 34.06% YoY increase from ₹38.29 Crores.

Thyrocare Technologies Limited is India’s leading fully automated diagnostic laboratory chain, specializing in preventive healthcare, pathology, and imaging services like PET-CT scans. During 2025, the company expanded its geographical presence and network capacity significantly, operationalizing multiple regional processing laboratories and maintaining strong test volume processing capabilities across India and international markets like Tanzania. The company continues to benefit from strong doctor trust, extensive active franchisee networks, and operational efficiencies. Prominent institutional investors such as mutual funds and foreign portfolio investors hold significant stakes in the company, alongside its promoter group, API Holdings (Docon).